[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hannah Harris\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":76},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100626381","early-phase-1-repeated-cbd-administration-and-cannabis-outcomes-100626381",false,"NCT07434895","Repeated CBD Administration and Cannabis Outcomes","The Effects of Repeated CBD Administration on Cannabis Abuse Liability and Analgesia: A Human Laboratory Study","Inclusion Criteria:\n\n* English-speaking, literate adults,\n* Male or female,\n* Between the ages of 18-55,\n* Body Mass Index from 18.5-32.0 kg\u002Fm2,\n* Not currently seeking treatment for cannabis or drug use,\n* Able to provide written informed consent and perform all study procedures,\n* If female, a negative pregnancy test and use of an effective form of contraception during study participation (e.g., oral contraceptive, abstinence, barrier method),\n* Negative urine drug test for drugs of abuse (other than cannabis) prior to every Laboratory Session, and\n* Otherwise healthy as determined by the investigator based on medical history, physical examination, vital signs, and laboratory chemistries.\n\nExclusion Criteria:\n\n* Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and\u002For alcohol that would require medical management,\n* Clinically significant acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders \\[e.g., asthma, COPD\\]),\n* Current or past history of major psychiatric disorder that would limit ability to participate in the study,\n* Use of cannabis exclusively for medical reasons (no recreational use reported),\n* Current, unrelenting chronic pain that prevents participation (i.e., unable to sit in chair for 8 hours),\n* Currently using daily prescription medications to manage medical conditions or any drug that could interfere with the study, including potent CYP2C9, CYP3A4, or CYP2C19 inducers,\n* Clinically significant abnormal ECG (as determined by study physician\u002Fcardiologist),\n* Clinically significant abnormal laboratory findings,\n* History of seizure disorder,\n* Clinically significant history of head injuries requiring medical management or long lasting sequalae, and\n* Self-report of past 30-day use of synthetic cannabis (i.e., K2, Spice).",true,"ALL","18 Years","55 Years",{"count":21,"type":22},23,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis.",[28,29,30],"Cannabis","Abuse Liability","Experimental Pain in Healthy Human Participants",[32,33,34],"marijuana","cannabidiol (CBD)","marijuana users","RECRUITING","2026-08-10",{"date":38,"type":39},"2026-08-12","ACTUAL",{"date":41,"type":39},"2026-08-05",{"date":43,"type":22},"2029-12-01",{"name":45,"class":46},"Hannah Harris","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":47},"100646059","early-phase-1-lung-health-and-breath-biomarkers-acute-effects-of-inhaled-cannabis-100646059","NCT07694466","Lung Health and Breath Biomarkers: Acute Effects of Inhaled Cannabis","Lung Health and Breath Biomarkers: Acute Effects of Combusted and Vaporized Cannabis Inhalation Compared to Tobacco Cigarette Combustion in the Human Laboratory","Inclusion Criteria:\n\n1. English-speaking,\n2. Literate adults,\n3. Male or female,\n4. Between the ages of 18 and 55,\n5. Body Mass Index from 18.5 and 32.0 kg\u002Fm2,\n6. Able to provide written informed consent and perform all study procedures,\n7. Current recreational cannabis users - must report past 30-day cannabis use and at least 5 exposures in the past year (minimum use criteria); no limit on maximum use,\n8. Past year history of vaporized or smoked cannabis use to intoxication,\n9. Past 30-day use of combusted tobacco,\n10. Not currently seeking treatment for cannabis, tobacco cigarettes, or other drug use,\n11. If female, a negative pregnancy test and use of an effective form of contraception during study participation (e.g., oral contraceptive, abstinence, barrier method),\n12. Negative urine drug test for drugs of abuse (other than cannabis) before every Laboratory Session, and\n13. Otherwise, healthy as determined by the investigator based on medical history, physical examination, vital signs, laboratory chemistries (blood chemistry with liver function tests and hematology, urinalysis, and microscopic evaluation, 12-lead electrocardiogram).\n\nExclusion Criteria:\n\n1. Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and\u002For alcohol that would require medical management,\n2. Clinically significant acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders \\[e.g., asthma, COPD\\]),\n3. Existing or significant lung health problems that could interfere with the study,\n4. Current or history of major psychiatric disorder that would limit the participant's ability to participate in the study (e.g., bipolar disorder),\n5. Exclusive use of tobacco or cannabis through vapes and Electronic Nicotine Delivery Systems (ENDS) products,\n6. Currently using daily prescription medications to manage medical conditions or any drug that could interfere with the study (as determined by the study physician),\n7. Clinically significant abnormal ECG (as determined by study physician\u002Fcardiologist),\n8. Clinically significant abnormal laboratory findings (e.g., liver function tests greater than 3x the upper limits of normal range),\n9. History of seizure disorder,\n10. Clinically significant history of head injuries requiring medical management or long-lasting sequelae.",{"count":56,"type":22},12,[25],"This outpatient study examines how inhaled cannabis, combustible or vaporized, alters lung health and breath biomarkers compared to a tobacco cigarette.",[60,61,62],"Cannabis Use","Tobacco","Biomarkers",[64,65,66],"vaping","cannabis","tobacco","NOT_YET_RECRUITING","2026-07-06",{"date":70,"type":39},"2026-07-10",{"date":72,"type":22},"2026-09-01",{"date":74,"type":22},"2027-06-01",{"name":45,"class":46},""]